By Dr. Brandon Bright, DAOM, LAc · Tustin, CA · June 5, 2026
NewLimit — Brian Armstrong’s longevity biotech — is doing ambitious epigenetic reprogramming work. If you’re wondering what it means for your longevity protocol today: the science is real, human therapies are 7-15 years out, and the practical wins still live in the protocols you can run now.
The 55-second answer
NewLimit is developing partial epigenetic reprogramming therapies using Yamanaka-factor approaches to roll back epigenetic age without erasing cell identity. Founded by Brian Armstrong, Blake Byers, Hannu Rajaniemi. Science is promising. In early safety stages as of mid-2026. Likely 7-15 years from broadly available patient therapy.
Practical longevity protocols you can run today still drive measurable biological-age improvements.
What epigenetic reprogramming is
Your DNA stays the same. Your epigenetic state changes — which genes on/off, how strongly. This drifts with age in characteristic patterns. Epigenetic clocks measure this drift.
Reprogramming: Rolling back that drift toward younger state. Shinya Yamanaka (2006) discovered four transcription factors (OSKM / Yamanaka factors) can reset adult cells to pluripotent stem cells.
Problem: full reprogramming erases cell identity. Your liver becomes a stem cell — great in a dish, catastrophic in your body.
Partial reprogramming: Apply Yamanaka factors briefly to roll back epigenetic age WITHOUT erasing cell identity. Belmonte (Salk, 2016) proved concept in mice. Sinclair (2023) extended it. Multiple biotechs racing to translate.
NewLimit specifically
- Founded 2021: Brian Armstrong, Blake Byers, Hannu Rajaniemi
- Funding: $100M+, Armstrong personally committed
- Approach: Computational search for transcription-factor combos that achieve partial reprogramming (liver first, then expansion)
- Pipeline: Pre-clinical + early Phase 1 safety as of mid-2026
- Strategy: Tissue-specific reprogramming, not whole-body
Rigorous team, credible, well-funded.
Realistic human timeline
Now (mid-2026): Pre-clinical work. No therapeutic candidates in regulatory pipelines.
3-5 years: Phase 1 safety trials in narrow indications. Likely first use: tissue-specific (liver, possibly retinal, muscle). Heavy regulatory scrutiny.
5-10 years: Phase 2/3 if safety/efficacy hold. First commercial therapies in narrow populations. Costs high, access limited.
10-15+ years: Broader longevity therapies if all goes well. Costs drop. “Epigenetic reprogramming for healthy aging” becomes patient story.
Worst case: Therapies fail trials. No broad access for 20 years.
For current 50-65 year-olds: Therapies maybe relevant in your 65-75 window (best case), 70-80 window (normal case), not accessible during remaining lifespan (worst case).
Don’t wait. Run protocols now. Measured bio-age improvements happen today with evidence-graded interventions.
What you can do today (evidence-graded)
Tier 1 — Strongest evidence, lowest barriers
- Sleep >7h, >85% efficiency — strongest healthspan evidence overall
- Resistance training 2-4x/week — strongest single intervention
- Mediterranean eating — strongest dietary evidence
- Stress regulation — chronic HPA activation major aging driver
- Comprehensive bloodwork 2x/year — foundational measurement
Tier 2 — Strong evidence, moderate barriers
- Personalized supplement protocols (bloodwork-based, combo-aware)
- Biological age testing (Horvath, GrimAge, DunedinPACE) — trend tracking
- Acupuncture + Chinese herbs — stress, sleep, pain, hormones
- Clinical hypnotherapy — stress, sleep, habit change
- Targeted peptide therapy via clinicians — specific indications only
- HRT for peri/menopausal — appropriate clinical evaluation
Tier 3 — Emerging evidence, higher barriers
- NAD+ precursors (NMN, NR) — plausible, data developing
- Senelytics (fisetin, quercetin) — plausible, data developing
- Rapamycin/rapalogs — strong animal data, limited human evidence
- Plasma exchange/TPE — early human data, expensive, limited access
- Comprehensive FM for chronic conditions
Tier 1 does more of the actual work. Don’t skip Tier 1 chasing Tier 3.
Three honest caveats
1. Don’t wait for reprogramming. 7-15 year timeline means run protocols NOW. Benefits compound while waiting.
2. NewLimit therapies aren’t available yet. Anyone selling “Yamanaka reprogramming now” is misrepresenting. Pipeline in regulatory development only.
3. Founder capital ≠ guaranteed outcome. Therapies fail trials. Timelines slip. Plan with realistic timelines.
→ Book first visit (Tustin clinic): $199 in-person, $150 virtual.
→ Join AI Longevity Pro beta: 90-day complimentary.
Dr. Brandon Bright, DAOM, LAc
Holistic and integrative medicine practitioner serving Tustin and patients nationwide.